glp 1 retatrutide 10mg & 20mg Research Peptide People dropped out of retatrutide

Description

This makes GLP-1R a key target for diabetes treatment

However, long-term safety remains unproven

Meissner WG, Remy P, Giordana C, Maltete D, Derkinderen P, Houeto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carriere N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O, Group LS (2024) Trial of Lixisenatide in early Parkinsons disease

Nekoei, S

Eight patients in the metformin group discontinued the study prematurely: 1 patient due to dyspepsia, 2 due to fatigue, 2 due to a lack of perceived efficacy, 2 due to worsening psychiatric symptoms and a consequent change of psychotropic medication, and 1 due to substance abuse